FINWIRES · TerminalLIVE
FINWIRES

Malaysian Shares End Flat Amid Softer Industrial Production Growth

By

Malaysian shares closed flat on Wednesday, with the FTSE Bursa Malaysia KLCI at 1,714.34 points, amid slower industrial production growth in July.

The country's industrial production index rose 4.7% year over year in July, according to data from the Department of Statistics Malaysia. The pace of growth was slower than the 6.5% increase recorded in the previous month and missed the consensus forecast of 5.4% tracked by Investing.com.

"Looking ahead, we remain cautiously optimistic that the continued AI boom/ global tech expansion will help underpin demand for Malaysia's production, whether from E&E or other tech-related sectors. This should help support IPI growth in the region of 4-5% for the full year, and real GDP growth of 4.9-5.1% for 2026. Resilient growth outlook is expected to provide the flexibility for BMM to adjust its monetary policy should growth or inflation risks surprise on the upside. We therefore foresee chance of a 25bps normalization in the OPR in the first half of next year," analysts at Hong Leong Bank wrote in a note.

In corporate news, shares of Farm Price (KLSE:FPHB) shed 1% at close after it completed the transfer of the listing and quotation of its entire issued share capital and warrants from Bursa Malaysia Securities' ACE Market to the Main Market.

Meanwhile, the local bourse is set to welcome a new company, with GB Bond (KLSE:GBBOND) seeking to raise 16.1 million ringgit via an initial public offering on the ACE Market of Bursa Malaysia.

On the flip side, Bursa Malaysia will delist the entire share capital of Pimpinan Ehsan (KLSE:PEB) from the main market, effective Sept. 14.

Related Articles

Asia

Canadian Phosphate Confirms Nine Kilometers Strike Continuity at Canada Project

Canadian Phosphate (ASX:CP8) confirmed around 9 kilometers of strike continuity at its Wapiti Project in British Columbia, with drilling extending phosphate mineralization along the eastern limb of the Red Deer Syncline, according to a Wednesday filing with the Australian bourse.The company has completed 18 holes spanning 2,638 meters, with first assays expected in September, while exploration has shifted to the western limb, using historical drilling to guide new targets, per the filing.The company will increase funding and expand drilling beyond the previously planned 3,000 meters, supported by light detection and ranging, orthoimagery, mapping and sampling to enhance resource potential and geological confidence, the filing said.The company has deferred the Barnes bulk sample to the second quarter of 2027, opting instead to use about 30,000 tonnes of previously mined phosphate rock in Montana to meet near-term customer demand while redirecting funding to its Wapiti exploration program, the filing added.

ASX:CP8
Asia

Market Chatter: Posco Union Workers Start Two-Day Partial Strike Over Wage Dispute

Posco (KRX:005490) union workers began the first day of their two-day partial strike on Wednesday after negotiations with management over wages and other compensation failed in South Korea, Yonhap News reported the same day.Workers began a 48-hour partial strike, with 40 participating employees at the Pohang plant and 80 at the Gwangyang plant. The union is seeking a 7.1% base pay raise, a 600% performance bonus, 50 company shares per worker and a 200% holiday bonus, while management has proposed a 2% wage hike, the report said.The steelmaker expects negligible impact on production due to the lower worker participation and plans measures to prevent overall operational disruptions, it said.Posco did not immediately respond to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

KRX:005490
Asia

HBM Partner Reports Positive Interim Results in Phase 2 Trial of Asthma Treatment

HBM Holdings' (HKG:2142) partner, Windward Bio AG, has reported positive interim results from the Phase 2 POLARIS-1 trial evaluating the company's treatment for asthma, according to a Tuesday bourse filing.The biopharmaceutical company said subjects responded well to its treatment, HBM9378/WIN378, during the trial conducted by Windward Bio, and observed no serious adverse events.HBM's partner has kicked off the Phase 3 trial and is also planning a second Phase 3 study, POLARIS-2, in the first half of next year.The company's shares were up 3% in early open-market trading in Hong Kong.

HKG:2142